Company Spotlight: Cue Biopharma Innovates in the Immunotherapy Space with its Immuno-STAT Platform
XTalks
AUGUST 17, 2020
With several biologics in the pipeline, including one in early stage clinical trials for head and neck cancer, the company is positioned to engineer highly specific biologics against immune targets in the body. In 2017, the US FDA approved a CAR-T cell treatment for young adults and children with B-cell ALL.
98 
Let's personalize your content